Travere Therapeutics Approval Travere Therapeutics, Inc., (TVTX) announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. In February 2023, based on the surrogate marker of proteinuria, FILSPARI was granted accelerated approval. Now, full approval has been granted based on positive long-term confirmatory results . . . This …
Prohost Letter #460 Treating IgA Nephropathy Immunoglobulin A (IgA), the antibody of the immune system known to fight infections, can itself cause two important diseases. It can attack the body causing autoimmune diseases and can build up glomeruli in the kidneys causing inflammation leading to a devastating disease known as IgA Nephropathy (IgAN) aka Berger’s Nephritis. IgAN makes it hard for the kidneys to filter …
Travere Therapeutics in the NEWS Yesterday, Feb. 15, 2024, Travere Therapeutics, Inc. (TVTX) reported its fourth quarter and full year 2023 financial results and provided a corporate update. Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics said, “With ongoing growth in demand for FILSPARI in IgAN and the initiation of the pivotal Phase 3 program of pegtibatinase in classical . . . …
The Bear Market The volatility in the Bear stock market continues to plunge the values of biotech stocks. The Bear market is sucking investors’ capitals who bet on firms with future growth potential based on early, mid term and late clinical trial results. Travere Therapeutics Good News On February 17, 2023, before the long weekend that ended on Tuesday, Travere Therapeutics (TVTX) announced …
It's Time to Remind About Travere Therapeutics The time has come to remind that the U.S. FDA is reviewing Travere Therapeutics’ (TVTX) New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for IgA Nephritis (IgAN). We remind that the FDA has assigned a Prescription Drug User Fee Act (
IgA Nephropathy Searching for companies focused on treating severe diseases that have yet to find approved drugs is one of Prohost Biotech's tasks. Recently we wrote about firms that have, in their pipelines, products that aim at treating NASH and ALS. Now, we are currently interested in finding firms that have products that can successfully treat IgA nephropathy, among other diseases that have yet to …
Travere Therapeutics Sparsentan for IgAN Positive Results Phase 3 PROTECT Study of Travere Therapeutics (TVTX) product sparsentan for the treatment of IgA nephropathy (IgAN) demonstrated positive topline interim results. The PROTECT Study met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater than a threefold reduction of proteinuria from baseline after 36 weeks of treatment . . . This content is for paid …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
